imm0306
Recombinant proteinexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 2, 2020 (NCT05805943)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Payload
- SIRP-alpha
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05771883 | Phase 1/Phase 2 (Phase 2) | May 31, 2023 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
| NCT04746131 | Phase 1 | Nov 15, 2021 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd, Worldwide Clinical Trials |
| NCT05805943 | Phase 1/Phase 2 (Phase 2) | Mar 2, 2020 | ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd | For profit | 3 | 3 | 2 | 2020 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1